ROVIELLO FRANCO | Elenco docenti

Petrioli, R., Marrelli, D., Roviello, F., D'Ignazio, A., Torre, P., Chirra, M., et al. (2020). Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer. SURGICAL ONCOLOGY, 32, 2-7. - dettaglio
Petrioli, R., Francini, E., Cherri, S., Marrelli, D., Roviello, F., Fiaschi, A.I., et al. (2020). Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer. ANTI-CANCER DRUGS, 31(3), 292-297. - dettaglio
Marano, L., Fusario, D., Savelli, V., Verre, L., Neri, A., Marrelli, D., et al. (2020). Robotic versus laparoscopic gastrectomy for gastric cancer: protocol for umbrella review of systematic reviews and meta-analyses. BMJ OPEN, 10(2), e033634. - dettaglio
Baiocchi, G.L., Giacopuzzi, S., Marrelli, D., Reim, D., Piessen, G., Matos da Costa, P., et al. (2019). International consensus on a complications list after gastrectomy for cancer. GASTRIC CANCER, 22(1), 172-189. - dettaglio
Polom, K., Das, K., Marrelli, D., Roviello, G., Pascale, V., Voglino, C., et al. (2019). KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status. PATHOLOGY ONCOLOGY RESEARCH, 25(1), 333-340. - dettaglio